These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 22226866)

  • 21. Fenofibrate Decreases Insulin Clearance and Insulin Secretion to Maintain Insulin Sensitivity.
    Ramakrishnan SK; Russo L; Ghanem SS; Patel PR; Oyarce AM; Heinrich G; Najjar SM
    J Biol Chem; 2016 Nov; 291(46):23915-23924. PubMed ID: 27662905
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fenofibrate does not affect burn-induced hepatic endoplasmic reticulum stress.
    Hiyama Y; Marshall AH; Kraft R; Arno A; Jeschke MG
    J Surg Res; 2013 Dec; 185(2):733-9. PubMed ID: 23866789
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapeutic potential of the dual peroxisome proliferator activated receptor (PPAR)α/γ agonist aleglitazar in attenuating TNF-α-mediated inflammation and insulin resistance in human adipocytes.
    Massaro M; Scoditti E; Pellegrino M; Carluccio MA; Calabriso N; Wabitsch M; Storelli C; Wright M; De Caterina R
    Pharmacol Res; 2016 May; 107():125-136. PubMed ID: 26976796
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Plasma triglycerides are not related to tissue lipids and insulin sensitivity in elderly following PPAR-alpha agonist treatment.
    Cree MG; Newcomer BR; Read LK; Sheffield-Moore M; Paddon-Jones D; Chinkes D; Aarsland A; Wolfe RR
    Mech Ageing Dev; 2007 Oct; 128(10):558-65. PubMed ID: 17904198
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High-fat diet-induced renal cell apoptosis and oxidative stress in spontaneously hypertensive rat are ameliorated by fenofibrate through the PPARα-FoxO3a-PGC-1α pathway.
    Chung HW; Lim JH; Kim MY; Shin SJ; Chung S; Choi BS; Kim HW; Kim YS; Park CW; Chang YS
    Nephrol Dial Transplant; 2012 Jun; 27(6):2213-25. PubMed ID: 22076434
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of cevoglitazar, a dual PPARalpha/gamma agonist, on ectopic fat deposition in fatty Zucker rats.
    Laurent D; Gounarides JS; Gao J; Boettcher BR
    Diabetes Obes Metab; 2009 Jun; 11(6):632-6. PubMed ID: 19175377
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fenofibrate inhibits adipocyte hypertrophy and insulin resistance by activating adipose PPARalpha in high fat diet-induced obese mice.
    Jeong S; Yoon M
    Exp Mol Med; 2009 Jun; 41(6):397-405. PubMed ID: 19322024
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The peroxisome proliferator-activated receptor (PPAR) α agonist fenofibrate suppresses chemically induced lung alveolar proliferative lesions in male obese hyperlipidemic mice.
    Kuno T; Hata K; Takamatsu M; Hara A; Hirose Y; Takahashi S; Imaida K; Tanaka T
    Int J Mol Sci; 2014 May; 15(5):9160-72. PubMed ID: 24857924
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reactivation of peroxisome proliferator-activated receptor alpha in spontaneously hypertensive rat: age-associated paradoxical effect on the heart.
    Purushothaman S; Sathik MM; Nair RR
    J Cardiovasc Pharmacol; 2011 Sep; 58(3):254-62. PubMed ID: 21654328
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The hepatokine FGF21 is crucial for peroxisome proliferator-activated receptor-α agonist-induced amelioration of metabolic disorders in obese mice.
    Goto T; Hirata M; Aoki Y; Iwase M; Takahashi H; Kim M; Li Y; Jheng HF; Nomura W; Takahashi N; Kim CS; Yu R; Seno S; Matsuda H; Aizawa-Abe M; Ebihara K; Itoh N; Kawada T
    J Biol Chem; 2017 Jun; 292(22):9175-9190. PubMed ID: 28404815
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synergistic improvement in insulin resistance with a combination of fenofibrate and rosiglitazone in obese type 2 diabetic mice.
    Choi WS; Lee JJ; Kim Y; Kim IS; Zhang WY; Myung CS
    Arch Pharm Res; 2011 Apr; 34(4):615-24. PubMed ID: 21544727
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia.
    Reifel-Miller A; Otto K; Hawkins E; Barr R; Bensch WR; Bull C; Dana S; Klausing K; Martin JA; Rafaeloff-Phail R; Rafizadeh-Montrose C; Rhodes G; Robey R; Rojo I; Rungta D; Snyder D; Wilbur K; Zhang T; Zink R; Warshawsky A; Brozinick JT
    Mol Endocrinol; 2005 Jun; 19(6):1593-605. PubMed ID: 15831517
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Osthole ameliorates insulin resistance by increment of adiponectin release in high-fat and high-sucrose-induced fatty liver rats.
    Qi Z; Xue J; Zhang Y; Wang H; Xie M
    Planta Med; 2011 Feb; 77(3):231-5. PubMed ID: 20717873
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fenofibrate attenuates cardiac and renal alterations in young salt-loaded spontaneously hypertensive stroke-prone rats through mitochondrial protection.
    Castiglioni L; Pignieri A; Fiaschè M; Giudici M; Crestani M; Mitro N; Abbate M; Zoja C; Rottoli D; Foray C; Fiordaliso F; Guerrini U; Tremoli E; Sironi L; Gelosa P
    J Hypertens; 2018 May; 36(5):1129-1146. PubMed ID: 29278547
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Peroxisome proliferator-activated receptor (PPAR) in metabolic syndrome and type 2 diabetes mellitus.
    Jay MA; Ren J
    Curr Diabetes Rev; 2007 Feb; 3(1):33-9. PubMed ID: 18220654
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of a potent and selective PPAR-alpha agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: two randomized controlled trials.
    Nissen SE; Nicholls SJ; Wolski K; Howey DC; McErlean E; Wang MD; Gomez EV; Russo JM
    JAMA; 2007 Mar; 297(12):1362-73. PubMed ID: 17384435
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Peroxisome proliferator-activated receptor-alpha gene level differently affects lipid metabolism and inflammation in apolipoprotein E2 knock-in mice.
    Lalloyer F; Wouters K; Baron M; Caron S; Vallez E; Vanhoutte J; Baugé E; Shiri-Sverdlov R; Hofker M; Staels B; Tailleux A
    Arterioscler Thromb Vasc Biol; 2011 Jul; 31(7):1573-9. PubMed ID: 21474829
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of stress-induced diabetes on outcomes in severely burned children.
    Finnerty CC; Ali A; McLean J; Benjamin N; Clayton RP; Andersen CR; Mlcak RP; Suman OE; Meyer W; Herndon DN
    J Am Coll Surg; 2014 Apr; 218(4):783-95. PubMed ID: 24655871
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Peroxisome proliferator-activated receptor (PPAR)-alpha activation prevents diabetes in OLETF rats: comparison with PPAR-gamma activation.
    Koh EH; Kim MS; Park JY; Kim HS; Youn JY; Park HS; Youn JH; Lee KU
    Diabetes; 2003 Sep; 52(9):2331-7. PubMed ID: 12941773
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of peroxisome proliferator-activated receptor-alpha and -gamma agonists on 11beta-hydroxysteroid dehydrogenase type 1 in subcutaneous adipose tissue in men.
    Wake DJ; Stimson RH; Tan GD; Homer NZ; Andrew R; Karpe F; Walker BR
    J Clin Endocrinol Metab; 2007 May; 92(5):1848-56. PubMed ID: 17327378
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.